Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task Force.

PerfO assessment patient focused drug development performance outcome assessment task performance

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
07 2023
Historique:
received: 06 03 2023
accepted: 05 05 2023
medline: 3 7 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

In evaluating the clinical benefit of new therapeutic interventions, it is critical that the treatment outcomes assessed reflect aspects of health that are clinically important and meaningful to patients. Performance outcome (PerfO) assessments are measurements based on standardized tasks actively undertaken by a patient that reflect physical, cognitive, sensory, and other functional skills that bring meaning to people's lives. PerfO assessments can have substantial value as drug development tools when the concepts of interest being measured best suit task performance and in cases where patients may be limited in their capacity for self-report. In their development, selection, and modification, including the evaluation and documentation of validity, reliability, usability, and interpretability, the good practice recommendations established for other clinical outcome assessment types should continue to be followed, with concept elicitation as a critical foundation. In addition, the importance of standardization, and the need to ensure feasibility and safety, as well as their utility in patient groups, such as pediatric populations, or those with cognitive and psychiatric challenges, may enhance the need for structured pilot evaluations, additional cognitive interviewing, and evaluation of quantitative data, such as that which would support concept confirmation or provide ecological evidence and other forms of construct evidence within a unitary approach to validity. The opportunity for PerfO assessments to inform key areas of clinical benefit is substantial and establishing good practices in their selection or development, validation, and implementation, as well as how they reflect meaningful aspects of health is critical to ensuring high standards and in furthering patient-focused drug development.

Identifiants

pubmed: 37385712
pii: S1098-3015(23)02598-6
doi: 10.1016/j.jval.2023.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

959-967

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Chris J Edgar (CJ)

Cogstate Ltd, London, UK. Electronic address: cedgar@cogstate.com.

Elizabeth Nicki Bush (EN)

Endpoints and Measurement Strategy, The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA.

Heather R Adams (HR)

University of Rochester, Rochester, NY, USA.

Rachel Ballinger (R)

Patient Centered Outcomes, ICON, St Albans, UK.

Bill Byrom (B)

Signant Health, Sandwich, UK.

Michelle Campbell (M)

Office of Neuroscience, Food and Drug Administration, Silver Spring, MD, USA.

Sonya Eremenco (S)

PRO Consortium, Critical Path Institute, Tucson, AZ, USA.

Fiona McDougall (F)

Genentech, South San Francisco, CA, USA.

Elektra Papadopoulos (E)

Patient Experience Data & Strategy in Immunology and Oncology, AbbVie, North Chicago, IL, USA.

Ashley F Slagle (AF)

Scientific and Regulatory Consulting, Aspen Consulting, LLC, Steamboat Springs, CO, USA.

Stephen Joel Coons (SJ)

Critical Path Institute, Tucson, AZ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH